ANN ARBOR, Michigan, Aug. 11 (TNSjou) -- Michigan Medicine, the academic medical center of the University of Michigan, issued the following news release:

* * *

Biomarkers aid cost-benefit analysis of head and neck cancer immunotherapy

Perioperative pembrolizumab is a promising but intensive option for advanced head and neck squamous cell carcinoma

-

The cost-effectiveness of the immunotherapy drug pembrolizumab for patients with lo . . .

Click here for more information about our products